New Clinical Score Can Predict Immune Checkpoint Blockade Response
By Elana Gotkine HealthDay Reporter
MONDAY, June 10, 2024 -- For patients with cancer, a novel clinical score using a six-feature regression model can predict immune checkpoint blockade (ICB) response probability and patient survival, according to a study published online June 3 in Nature Cancer.
Tian-Gen Chang, Ph.D., from the National Institutes of Health in Bethesda, Maryland, and colleagues analyzed a large dataset of 2,881 ICB-treated and 841 non-ICB-treated patients across 18 solid tumor types. A clinical logistic regression-based immunotherapy-response score (LORIS) was developed using a six-feature logistic regression model.
The researchers found that LORIS outperformed previous signatures for predicting ICB response and identifying responsive patients, including those with low tumor mutational burden and with programmed cell death 1 ligand 1 expression. Patient objective response and short- and long-term survival were consistently predicted by LORIS across most cancer types. A near-monotonic relationship with ICB response probability and patient survival was seen with LORIS, enabling precise patient stratification.
"As our understanding of tumor immunology and the availability of comprehensive data in larger cohorts continue to improve, we expect to see the development of even more accurate models for personalized precision therapy, ultimately reducing cancer mortality," the authors write.
One author disclosed ties to MedAware, Metabomed, and Pangea Biomed.
Abstract/Full Text (subscription or payment may be required)
Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.
© 2025 HealthDay. All rights reserved.
Posted June 2024
Read this next
Testosterone Use Not Tied to Gynecological Cancers in Transmasculine Individuals
FRIDAY, May 16, 2025 -- Short-term testosterone use among transmasculine and gender diverse (TMGD) individuals is not associated with an increased risk for gynecological cancers...
Increases in Incidence Rates of Some Cancers Seen in Early-Onset Age Groups
THURSDAY, May 15, 2025 -- The incidence rates of 14 cancers have increased in early-onset age groups, with increases in older-onset age groups also occurring in most of these...
Aqueous Humor Liquid Biopsy Safe in Pediatric Retinoblastoma
WEDNESDAY, May 14, 2025 -- For pediatric patients with retinoblastoma, aqueous humor liquid biopsy via anterior chamber paracentesis is a safe and well-tolerated procedure...
More news resources
- FDA Medwatch Drug Alerts
- Daily MedNews
- News for Health Professionals
- New Drug Approvals
- New Drug Applications
- Drug Shortages
- Clinical Trial Results
- Generic Drug Approvals
Subscribe to our newsletter
Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.